Nuwellis Receives New US Patent Reinforcing Vivian(TM) Pediatric Device Focused on Safer, More Precise Ultrafiltration
MWN-AI** Summary
Nuwellis, Inc., based in Eden Prairie, Minnesota, has announced a significant advancement with the issuance of U.S. Patent No. 12,415,021 on September 16, 2025. This patent pertains to the incorporation of hemolysis sensors in extracorporeal blood filtration systems, specifically aimed at ultrafiltration therapy and continuous renal replacement therapy (CRRT). The ability to detect and localize red blood cell destruction is crucial, as hemolysis can release free hemoglobin into the bloodstream, jeopardizing patient safety by diminishing oxygen transport capabilities.
The newly patented technology addresses a critical gap in standard blood-leak detection, which traditionally focuses on intact red blood cells and may overlook hemolyzed blood, leading to misleading diagnostics. By enabling hemolysis sensing at both the circuit inlet and the ultrafiltrate line, care teams can determine whether hemolysis occurs internally or externally, fostering quicker and more effective responses to patient needs.
John Erb, CEO of Nuwellis, emphasized that protecting intellectual property related to sensing and signal interpretation is vital for enhancing fluid management safety. This patent not only bolsters the development of Vivian™, a pediatric device specifically designed for neonates and children, but also underpins Nuwellis’ commitment to innovation in this critical medical field.
Vivian is engineered to manage extracorporeal blood volumes for young patients, combining multiple therapies on one platform while ensuring ease of use through innovative design. The system has been developed with input from pediatric healthcare professionals to prioritize safety.
As Nuwellis continues to advance its commercial strategy and seek growth opportunities in the evolving healthcare landscape, its focus remains on delivering safer and more precise dialysis solutions for vulnerable patient populations.
MWN-AI** Analysis
Nuwellis, Inc. recently secured a significant advancement with the issuance of U.S. Patent No. 12,415,021, reinforcing its commitment to enhancing pediatric care through its Vivian™ device. This patent pertains to innovative hemolysis sensors integrated into extracorporeal blood filtration systems, a critical aspect as the medical community recognizes that hemolysis, the breakdown of red blood cells, can severely compromise patient safety and treatment efficacy in ultrafiltration and continuous renal replacement therapy (CRRT).
The implications of this patent for Nuwellis are manifold. By incorporating hemolysis detection capabilities, Nuwellis not only strengthens the functionality and safety of Vivian, designed specifically for vulnerable pediatric populations, but it also introduces a new standard of care in fluid management. The ability to differentiate between extrinsic and intrinsic hemolysis will allow healthcare professionals to make more informed decisions promptly, potentially improving patient outcomes and reducing risks associated with treatment.
From an investment perspective, this patent is a substantial value addition for Nuwellis, as it not only reinforces their intellectual property portfolio but also showcases their dedication to innovation in pediatric medicine. The patent supports future developments, potentially paving the way for Nuwellis to expand its market reach and solidify its competitive position against other players in the medical device landscape.
Investors should consider the implications of this development in relation to Nuwellis' current market performance (NASDAQ: NUWE). Increased focus on pediatric health technology, alongside the growing shift towards personalized medicine, positions Nuwellis favorably for growth. However, potential investors should also heed caution regarding inherent risks associated with commercialization strategies and financial dependencies noted in the company's forward-looking statements. Overall, Nuwellis may present a compelling opportunity for growth-oriented investors in the health tech sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
EDEN PRAIRIE, Minn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc., a fluid management company, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,415,021 on September 16, 2025, based on Application No. 18/298,860.
The patent relates to the use of one or more hemolysis sensors with extracorporeal blood filtration systems—such as ultrafiltration therapy and continuous renal replacement therapy (CRRT)—to help detect and localize red blood cell destruction occurring within or around the circuit. The intellectual property supports Nuwellis’ pediatric device, Vivian, in development and future platform innovation.
Why hemolysis matters
Hemolysis is the destruction of red blood cells, which releases hemoglobin and reduces oxygen-carrying capacity. Significant hemolysis is dangerous for patients. In extracorporeal therapies, red cell fragments and free hemoglobin can pass through a filter and may tint the ultrafiltrate pink or red, resembling a filter issue. Standard blood-leak detectors typically look for intact cells and may not flag hemolyzed blood.
What the patent enables
The patent covers configurations that use hemolysis sensing at the circuit inlet and on the ultrafiltrate line, with the option to compare readings. This approach may help care teams assess whether hemolysis originates outside the system or within the extracorporeal circuit and respond appropriately.
“Protecting IP around sensing and signal interpretation is central to how we advance fluid management safety,” said John Erb, Chief Executive Officer of Nuwellis. “This patent strengthens our pediatric roadmap and underscores our focus on technologies that give care teams clearer information during ultrafiltration.”
For more information, visit www.nuwellis.com .
About Vivian Vivian is a purpose-built pediatric CRRT system designed for neonates and children. The platform targets an extracorporeal blood volume of 29–67 mL and features integrated hematocrit and SvO? sensors for real-time monitoring. Vivian brings three therapies—Ultrafiltration (UF), Continuous Veno-Venous Hemofiltration (CVVH), and Continuous Veno-Venous Hemodialysis (CVVHD)—onto a single platform with closed-loop ultrafiltration control tailored to patient weight. A guided, clinician-informed interface with on-screen prompts streamlines setup and reduces training burden, while a 6-port circuit provides flexible vascular-access options. Intended for patients 2.5–20 kg, Vivian was developed with direct input from pediatric ICU and nephrology teams to prioritize safety, precision, and simplicity for the most fragile patients.
Disclaimer: Vivian is an investigational device, under development, and not available for sale. Features and specifications are subject to change.
About Nuwellis Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow ® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn or X, formerly known as Twitter.
Forward-Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2025 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.
For further information, please contact:
Investor Relations:
Jenene Thomas
JTC
NUWE@JTC.com
Media Contact:
Leah McMullen
Director of Communications
Leah.mcmullen@nuwellis.com
FAQ**
How does Nuwellis Inc. (NUWE) plan to leverage U.S. Patent No. 12,415,021 to differentiate its pediatric device, Vivian, from other extracorporeal blood filtration systems currently on the market?
What specific steps is Nuwellis Inc. (NUWE) taking to ensure that the hemolysis sensors become a key feature in the commercialization of Vivian and other future platforms?
Given the critical nature of hemolysis detection, what partnerships or collaborations does Nuwellis Inc. (NUWE) envision to enhance the safety and efficacy of its fluid management technologies?
How does Nuwellis Inc. (NUWE) anticipate the new patent will impact the acceptance of the Vivian system among pediatric ICU and nephrology teams, especially considering its focus on fragile patients?
**MWN-AI FAQ is based on asking OpenAI questions about Nuwellis Inc. (NASDAQ: NUWE).
NASDAQ: NUWE
NUWE Trading
-2.69% G/L:
$1.0996 Last:
18,248 Volume:
$1.09 Open:
